LEO Pharma has just introduced Enstilarpsoriasis vulgaris to treat adults. It is a skin foam, “which has proven superior to other treatments such as corticosteroids effectiveness,” according to the company. More than half of patients have been treated with this treatment achieved a complete or almost fully bleached skin after four weeks of application. Also they achieved a 75 percent improvement in the Index Psoriasis Area and Severity, which until now “only be achieved with systemic or biologic treatments,” detailing those responsible. “The foam formulation allows high solubility of the active ingredient, providing greater penetration and therefore more effective,” said the head of Department of Dermatology, University Hospital of the Princess of Madrid, Esteban Daudén.
This foam is now available on the market, and presented at the 45 National Congress of Dermatology Venereology and AEDV, bringing together dermatologists from around the world at the Palacio Municipal de Congresos in Madrid until next May 13.
Enstilar combines analog of vitamin D (calcipotriol) with a corticosteroid (betamethasone dipropionate) to achieve a normalizing results in skin cells that are affected by psoriasis. Thus, “it promotes greater antipsoriatic response than if the components acting alone” explained.
The CEO of LEO Pharma Spain and vice president of the Southern Region of Europe, Paolo Cionini, stressed that this release is “great news for people who live daily with psoriasis” as it is “a breakthrough that will change the standard topical “treatment of this skin pathology. Cionini explained that the coming to market this new treatment is part of the commitment of LEO Pharma with dermatological diseases such as psoriasis, actinic keratosis, skin infections or atopic dermatitis. “We believe so much in this mission that in recent years have made significant investments in research and acquisitions to rapidly provide adequate therapies for these conditions,” he stressed.
In Europe, an estimated 3.7 million people suffer from psoriasis vulgaris, the most common form of psoriasis, which affects men and women equally. It is a chronic inflammatory disease that, if not treated properly, “has a major negative impact on the quality of life of patients because it involves multiple physical and psychological comorbidities such as metabolic syndrome and psoriatic arthritis” point. Topical treatments are first-line therapies and can be of great help to most patients with psoriasis.